Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto drives down markets
Mon, 16 May 11:30 am

Indian stock markets continued to sink deeper in the red on sell off in heavy weights over the last two hours of trade. Stocks from the auto and metals space are trading weak while stocks from the healthcare space are trading firm.

The BSE-Sensex is down by 153 points while NSE-Nifty is trading 37 points below the dotted line. BSE Midcap index is down by 0.5% while BSE Small cap index is trading 0.3% below Monday's closing. The rupee is trading at 45.05 to the US dollar.

Pharma stocks are trading firm led by Glenmark Pharma and Wockhardt. As per a press release by Glenmark Pharma, its wholly owned subsidy Glenmark Pharmaceuticals SA has entered into a license agreement with global pharma major Sanofi for development and commercialization of GBR500. GBR 500 is a monoclonal antibody to treat Crohn's disease as well as other chronic autoimmune disorders.

As per the agreement, Glenmark will receive an upfront payment of US$ 50 m from Sanofi. This payment includes US$ 25 m on closing of the deal and the remaining US$ 25 m on assessment by Sanofi of certain data to be provided by Glenmark. In addition to the payment, Glenmark could potentially receive payment for success-based development and regulatory and commercial milestones. As per the agreement, Sanofi will have the exclusive marketing rights for North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay. In addition, the company will have co-marketing rights in Brazil, Russia, Australia and New Zealand. Glenmark would receive double-digit royalties on sales of products under this license. For India and rest of the world, Glenmark will have exclusive marketing rights.

Hotel stocks are trading mixed with Oriental Hotels and Country Club trading firm while Indian Hotel and Hotel Leelaventure are trading weak. As per the Chairperson and CEO of EIH Limited, Mr P.R.S Oberoi, 60% of the company's business in 10 years time will come from management contracts. This is as the company is shifting its focus away from owning real estate. However, the company will develop the land it already owns. EIH which owns around 30 properties under the Oberoi and Trident brands has recently began to take up hotels on management contract. In this business model, hotel companies operate their brands in properties owned by someone else for a fee. EIH is currently charging a management contract fee of 12-16% of net profits. EIH operates in the five star (Trident) and luxury (Oberoi) segments and plans to continue to operate in these segments only.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto drives down markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.